Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advil Multi-Symptom Cold

This article was originally published in The Tan Sheet

Executive Summary

New Advil line extension combines ibuprofen 200 mg with pseudoephedrine HCl 30 mg and the antihistamine chlorpheniramine maleate 2 mg, Wyeth Consumer Healthcare says. A 10-count package of coated capsules retails for $5.49 while a 30-count sells for $9.49. Wyeth initiated an FSI drop in November, but ads for the product have not yet broken. The new SKU also is being supported by in-store displays...

New Advil line extension combines ibuprofen 200 mg with pseudoephedrine HCl 30 mg and the antihistamine chlorpheniramine maleate 2 mg, Wyeth Consumer Healthcare says. A 10-count package of coated capsules retails for $5.49 while a 30-count sells for $9.49. Wyeth initiated an FSI drop in November, but ads for the product have not yet broken. The new SKU also is being supported by in-store displays....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel